Immunocore Holdings plc
Close on Oct 19, 2026
- Market cap
- $1.52B
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Earnings
Next report expected Nov 5, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | $115.90M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 6, 2026 | Before market open | $106.70M | $0.25 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 25, 2026 | Before market open | $104.50M | $-0.60 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | $103.70M | $0.00 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | $97.96M | $-0.20 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 7, 2025 | Before market open | $93.88M | $0.10 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 26, 2025 | Before market open | $84.10M | $-0.47 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | Before market open | $80.25M | $0.17 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 28, 2024 | After market close | – | – | – |
Press releases
Announcements Immunocore filed with the SEC
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK ® (tebentafusp) in previously treated advanced melanoma
Regulation FD disclosure · EX-99.1 to Form 8-K
Immunocore reports second quarter financial results and provides a business update
Results of operations · EX-99.1 to Form 8-K
Immunocore reports first quarter financial results and provides a business update
Results of operations · EX-99.1 to Form 8-K
Immunocore reports fourth quarter and full year 2025 financial results and provides a business update
Results of operations · EX-99.1 to Form 8-K
Immunocore announces 2026 strategic priorities at 44 th Annual J.P. Morgan Healthcare Conference
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Transformative immunomodulating medicines for patients January 2026 1
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
universal for all populations). *ID = Infectious diseases Leading bispecific TCR pipeline Candidate Target (HLA type) Indication Pre IND Phase 1 Phase 2 Phase 3 Approved gp100-A02 Uveal (ocular) melanoma Adjuvant uveal (ocular)
Results of operations · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Immunocore reports third quarter financial results and provides a business update
Results of operations · EX-99.1 to Form 8-K
Immunocore reports second quarter financial results and provides a business update
Results of operations · EX-99.1 to Form 8-K
Immunocore reports first quarter financial results and provides a business update
Results of operations · EX-99.1 to Form 8-K
Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
Immunocore reports fourth quarter and full year 2024 financial results and provides a business update
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Immunocore announces strategic priorities at 43 rd Annual J.P. Morgan Healthcare Conference
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Transformative immunomodulating medicines for patients January 2025 1
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
cell lung cancer 3 Program is wholly owned, development costs being provided by the Bill & Melinda Gates Foundation (BMGF), Immunocore retains all development and commercialization rights in the developed world. 4 Program is not HLA
Results of operations · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Immunocore appoints Travi s Coy, previously a Non-Executive
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Immunocore reports third quarter financial results and provides a business update
Results of operations · EX-99.1 to Form 8-K
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with
Other events · EX-99.1 to Form 8-K
Immunocore announces transition of Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Immunocore reports second quarter financial results and provides a business update
Results of operations · EX-99.1 to Form 8-K
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously
Other events · EX-99.1 to Form 8-K
Immunocore reports first quarter financial results and provides a business update
Results of operations · EX-99.1 to Form 8-K
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Transformative immunomodulating medicines for patients 4Q 2023 & FY 2023
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Immunocore Prices Upsized Convertible Senior Notes Offering
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Immunocore Announces Proposed Convertible Senior Notes Offering
Results of operations · Other events · EX-99.1 to Form 8-K
In the confidential preliminary offering memorandum
Results of operations · Other events · EX-99.2 to Form 8-K
Immunocore announces strategic priorities and pipeline expansion ahead of 42 nd
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Transformative immunomodulating medicines for patients January 2024
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
5 1 Platinum refractory or resistant serous ovarian carcinoma.; 2. Program is
Results of operations · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Unaudited Condensed Consolidated Interim Financial Statements
EX-99.1 to Form 6-K
Unaudited Condensed Consolidated Interim Financial Statements
EX-99.1 to Form 6-K
Unaudited Condensed Consolidated Interim Financial Statements
EX-99.1 to Form 6-K